

ISPOR 2024 PRESENTATIONS

Explore the 70+ presentations using MarketScan real-world data

We're excited to share that this year at the ISPOR Global Conference, more than 70 accepted poster and podium presentations leverage MarketScan real-world data. Of those, 15 posters were coauthored by our MarketScan researchers, including two in the top 5% finalists for the ISPOR Research Presentation Awards. Below is the complete list of presentations. MarketScan coauthored posters are denoted in bold.

Podium Session, Monday, May 6, 10:15AM-11:15AM

- **109:** Economic Impact of Rare Diseases
- **P4:** Is later diagnoses of rare diseases associated with higher medical costs? Real-world evidence for Duchenne/Becker muscular dystrophy

Poster Session 1, Monday, May 6, 10:30AM-1:30PM

- **CO30:** Comparative Genitourinary Safety of in-Class Sodium Glucose Co-Transporter-2 Inhibitors Among Patients with Heart Failure with Preserved Ejection Fraction
- **CO41:** Comparative Effectiveness of Glucagon-like Peptide 1 Agonists Vs Dipeptidyl Peptidase 4 Inhibitors on Liver Outcomes in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Fatty Liver Disease
- **EE36:** Comparison of Healthcare Resource Utilization and Costs in Patients With Venous Thromboembolism Receiving Direct-Acting Oral Anticoagulants or Low Molecular Weight Heparins: A Real-World Data Analysis
- **EE73:** Direct Healthcare Costs Associated With Primary Symptomatic Cytomegalovirus in the United States
- **EE85:** Sources of Increased Expenditures for Young Children with Autism Spectrum Disorder Diagnoses in Employer-Sponsored Plans, 2016–2021
- **EE54:** A Framework for Evaluating the Economic Impact of Artificial Intelligence for Screening Mammography: Implications for Facilities and Payers from the US Perspective

- **EE78: Economic and Comorbidity Burden of Prurigo Nodularis and Drivers of Higher Healthcare Costs in the US: A Retrospective Analysis of Claims Data of Patients Diagnosed Between 2017 and 2022**
- **EPH7: Examination of Weight-Related Coding Practices in Administrative Claims – Implications for Future Analyses**
- **EPH26: Claims-Based Analysis of the Prevalence, Characteristics, Healthcare Utilization and Costs of Adolescents and Young Adults with Non-Remission Major Depressive Disorder in the United States**
- **EPH1: High Throughput Screening for Roflumilast Adverse Effects in Real-World Settings: A Sequence Symmetry Analysis**
- **HSD27: Patterns of Postoperative Opioid Dispensing for Common Surgical Procedures Among Medicaid Beneficiaries in 2020-2021**
- **RWD18: Healthcare Costs Associated With Type 1 Diabetes in Adults With a Commercial, Medicaid, or Medicare Coverage in US Clinical Practice**
- **RWD6: Effect of Selumetinib Treatment on Pain Medication Utilization in Pediatric Patients: A US Claims Database Analysis**
- **RWD5: A Novel Predictive Model for Agitation in Alzheimer's Dementia Using Administrative Claims Data**
- **SA2: A Unique Approach for Identifying Thoracic Endovascular Aortic Repair Stent Graft Landing Zones 0/1/2 Using Revascularization Procedure Codes from a Commercial Claims Database**

Poster Session 2, Monday, May 6, 3:30PM-6:30PM

- **CO74: Hospitalizations with Initiation of Hydroxychloroquine in Patients with Heart Failure with Preserved Ejection Fraction and Autoimmune Disease**
- **CO58: Disease- and Glucocorticoid-Related Comorbidities in Classic Congenital Adrenal Hyperplasia: A Claims-Based Retrospective Cohort Analysis**
- **EE132: Economic Outcomes and Real-World Adherence of Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises Treated with L-Glutamine, Voxelotor, and Crizanlizumab in the United States**
- **EE149: Economic burden of treating chronic peripheral neuropathic pain in the United States: National estimates from 2022 data**
- **EE137: Economic Burden for Adults With Sickle Cell Disease and Matched Controls in the United States: Retrospective Analysis of a Commercial Insurance Database**
- **EPH66: Pre-Exposure Prophylaxis Adherence Trajectories and HIV and Sexually Transmitted Infections Risk**
- **EPH89: Telehealth Utilization Among Children with Autism Spectrum Disorder in Employer-Sponsored Plans, 2019–2022**
- **HPR44: Implications of Regulatory Telemedicine Prescribing Flexibilities on Patients With Opioid Use Disorder**
- **HSD33: Contraceptive Use Among Female Patients Who Underwent Bariatric Surgery in the U.S. Commercial Insurance Plans**

- **HSD37:** Prescribing Trends of Newly Approved Sickle Cell Disease-Modifying Medications
- **HSD54:** Assessing the Impact of Telehealth Delivery on Adherence to Medications for Opioid Use Disorder
- **HSD32:** Treatment Patterns and Healthcare Resource Use Among Patients With Axial Spondyloarthritis and Comorbid Inflammatory Bowel Disease
- **HSD47:** Treatment Response, Healthcare Resource Use, and Economic Outcomes Associated With Tumor Necrosis Factor Inhibitor Cycling Versus Switching to an Advanced Therapy With Different Mechanism of Action in Rheumatoid Arthritis
- **PT20:** Gleaning Novel Insights from Real World Data: A Machine-Learning Guided Analytical Framework
- **RWD41:** Adherence Trajectories in Medicaid Drug-Naïve Type 2 Diabetes Patients: A Comparative Study between Initial Combination Therapy and Step-Therapy Approaches
- **RWD65:** Characteristics of Real-World Databases in the United States: A Systematic Review
- **RWD69:** Utilization of Current Procedural Terminology Codes in Pharmacists' Services Using Medicare Data Claims
- **SA9: Validation of a Claims-Based Algorithm to Identify Major Congenital Malformations in Infants using a Linked Claims-EMR Database**

Poster Session 3, Tuesday, May 7, 10:30AM-1:30PM

- **CO117:** Factors Associated with Biologic Treatment De-Escalation in Patients with Crohn's Disease
- **EE218:** Assessment of Unmet Clinical Needs and Healthcare Resource Use Among Statin-Treated Patients with or at Risk of Developing ASCVD
- **EE253: An evaluation of the prevalence of diagnosed Opioid Use Disorder (OUD) and the economic burden of OUD-related healthcare costs in the United States**
- **EE295: Economic Burden Associated with Managing Patients with Sickle Cell Disease Receiving Frequent Red Blood Cell Transfusions in the United States**
- **EPH21:** Prevalence and Correlates of Alcohol Use Disorder Diagnosis Among Cancer Survivors in the United States: Insights From a Real-World Study
- **MT23:** The Changing Healthcare Landscape of Lumbar Spinal Fusion: Two-Year Claims Database Analysis
- **MSR48:** Utilization of High-Dimensional Propensity Score and Targeted Maximum Likelihood Estimation with Machine Learning to Improve Causal Effect Estimation in Patients with Nonvalvular Atrial Fibrillation and Hypertension
- **MSR51:** Evaluation of Machine Learning Approaches in Predicting the Initial Treatment Strategy in Patients with Multiple Sclerosis
- **MSR63:** Improving Efficiency in Analysis of Real-World Data with an Automated Machine Learning Tool
- **PCR149:** Buprenorphine Adherence Trajectories, Persistence, and Healthcare Expenditures Among Commercially Insured Patients with Opioid Use Disorder

- **PCR158:** Assessing the Cost of Work Productivity Loss in a Privately Insured US Population with Inflammatory Bowel Diseases
- **RWD115: Is More Always Better? A Real-World Data Analysis of Hemoglobin A1C Data in Patients with Diabetes**
- **PT36:** Use and Discontinuation Rates of Long-Acting Injectable Antipsychotics between Race/Ethnicity in Older Adults Using Medicaid Claims Data
- **RWD96:** Risk of Venous Thromboembolism with Janus Kinase Inhibitors in Rheumatoid Arthritis: A Systematic Review
- **RWD105:** The Clinical and Economic Burden of Woman with Endometriosis (EM)
- **SA16: Estimating Infant Date of Birth in Administrative Claims Databases: A Comparison of Exact Date of Birth and Date of Birth Proxies**

Poster Session, Tuesday, May 7, 1:45PM – 2:45PM

- **230:** Pricing and Regulatory Policies: Implications for Pharmaceutical Manufacturers
- **P34:** National Costs of Prescription Drug Market Exclusivity Extensions

Poster Session 4, Tuesday, May 7, 3:30PM-6:30PM

- **EE405:** Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa
- **EE379:** Assessing Trends in the Distribution of Prescription Claim Payments (2011-2021) and Implications for Retail Pharmacies
- **EE389:** Economic Burden of Diagnosed Congenital Cytomegalovirus in the United States and Japan
- **EE368: Claims-Based Comparison of Characteristics and Healthcare Costs Between Mothers with and without Postpartum Depression**
- **EE324: Describing the Clinical and Economic Burden of Women Diagnosed with Uterine Fibroid (UF) and Heavy Menstrual Bleeding (HMB) in a United States (US) Commercial Database 2015-2022**
- **EE359: Economic burden of managing acute and chronic pain in the United States: National estimates from 2022 data**
- **HSD84:** Prescription Contraceptive Use Among Medicaid-Insured Women With Obesity in the United States
- **HSD88:** The Impact of Diagnosing Provider Type on Longitudinal Care for Patients With Newly Diagnosed Huntington's Disease (HD)
- **RWD154: Evaluation of Mortality Data Sources for Use in Real-World Data Analyses**
- **SA66:** Patient Demographic and Clinical Characteristics Associated With the Use of the Newly Approved Disease-Modifying Medications for Sickle Cell Disease
- **SA63:** Comparative Analysis of Recurrence and Healthcare Expenditures After Primary Inguinal Hernia Repair Using Robotic-Assisted, Laparoscopic, and Open Surgical Approaches

Poster Session 5, Wednesday, May 8, 9:00AM-11:30AM

- **CO187:** Acute Pancreatitis Risk Associated with Glucagon-Like Peptide-1 Receptor Agonists Used for Weight Loss: A Retrospective Cohort Study in the United States
- **EE425:** A Comparison of Payer Costs for Patients with and without Revascularization in Thoracic Endovascular Aortic Repair Stent Grafting Procedures
- **EPH196: A Claims-Based Analysis of Weight Management in Pediatric Populations Covered by Commercial or Medicaid Insurance**
- **HSD113:** Treatment Patterns, Comorbidities, Healthcare Resource Utilization and Related Costs of Dermatomyositis and Polymyositis in the United States: A Cohort Study in the Merative™ MarketScan® Database
- **HSD122:** Medication Adherence, Persistence, and Treatment Switching in Patients Receiving Advanced Therapies for Rheumatoid Arthritis in Clinical Practice
- **MT41:** Outcomes and Costs Associated with Cervical Spinal Fusion Surgery
- **PCR240:** Medication Adherence to Direct Acting Anti-Viral Agents Among Hepatitis C Virus Infected Patients in the United States
- **RWD181:** Healthcare Costs Associated With Newly Diagnosed Type 1 Diabetes in Children With Commercial Health Plan or Medicaid Coverage in US Clinical Practice
- **RWD192:** Real-World Use of Tirzepatide Among People Without Evidence of Type 2 Diabetes: Results From Merative MarketScan Commercial Database
- **RWD163:** Medication Adherence and Persistence on Selumetinib Treatment in Pediatric Patients: A US Claims Database Analysis
- **RWD172:** Healthcare Utilization and Costs Among Patients With Episodic Migraine Initiating Galcanezumab Versus Rimegepant for Migraine Prevention in the United States